Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status:
Recruiting
Trial end date:
2025-11-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine what effects (good and bad) cabozantinib has in
treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
The hypothesis for this trial is that cabozantinib has anti-tumor activity in a
molecularly-selected group of patients with CRPC.